Sigma Planning Corp Sells 3,208 Shares of BeOne Medicines Ltd. - Sponsored ADR $ONC

Key Points

• Sigma Planning Corp cut its stake by 76.1%, selling 3,208 shares of BeOne Medicines and retaining 1,005 shares valued at about $305,000 per its SEC filing.
• BeOne missed Q1 expectations, reporting $0.25 EPS vs. $0.73 consensus on $1.51 billion in revenue, although FY‑2026 revenue guidance of roughly $6.3–6.5 billion was in line with analysts.
• Analysts remain largely bullish—several firms raised ratings/targets (RBC $425, Truist $413, Wells Fargo "strong-buy"), leaving an average target of $391 while the stock trades near $317 with a market cap around $34.8 billion.

Sigma Planning Corp reduced its holdings in shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) by 76.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,005 shares of the company's stock after selling 3,208 shares during the quarter. Sigma Planning Corp's holdings in BeOne Medicines were worth $305,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Daiwa Securities Group Inc. bought a new position in shares of BeOne Medicines during the second quarter valued at $35,000. CWM LLC lifted its holdings in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company's stock valued at $48,000 after purchasing an additional 39 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of BeOne Medicines by 21.8% during the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company's stock valued at $66,000 after purchasing an additional 39 shares in the last quarter. EverSource Wealth Advisors LLC bought a new position in shares of BeOne Medicines during the second quarter valued at $68,000. Finally, Signaturefd LLC lifted its holdings in shares of BeOne Medicines by 10.7% during the fourth quarter. Signaturefd LLC now owns 340 shares of the company's stock valued at $103,000 after purchasing an additional 33 shares in the last quarter. 48.55% of the stock is owned by institutional investors.

BeOne Medicines Stock Up 1.2%

BeOne Medicines stock opened at $317.00 on Friday. The stock has a market cap of $34.78 billion, a PE ratio of 70.92 and a beta of 0.50. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.08 and a current ratio of 3.41. BeOne Medicines Ltd. - Sponsored ADR has a one year low of $218.31 and a one year high of $385.22. The stock has a fifty day moving average of $301.40 and a 200 day moving average of $322.00.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The business had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.55% and a net margin of 8.94%. As a group, sell-side analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post 5.44 EPS for the current year.

Key Headlines Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Royal Bank of Canada raised its price target to $425 and kept an "outperform" rating, implying ~34% upside from the recent price — a clear bullish signal for investors. Article Title
• Positive Sentiment: Truist reaffirmed a "buy" rating and nudged its target to $413 (from $411), another analyst endorsement supporting upward momentum. Article Title Ticker Report
• Positive Sentiment: Wells Fargo upgraded ONC to "strong-buy," adding to the cluster of bullish broker actions that can attract inflows from institutional and quant-driven funds. Zacks Article
• Positive Sentiment: Market reaction: reports note shares surged on what analysts and media called a "robust" Q1 — momentum that reinforces the price action from the broker notes. MarketWatch: Shares Surge
• Neutral Sentiment: The company issued FY‑2026 revenue guidance roughly in line with consensus (~$6.3B–$6.5B vs. $6.4B consensus), which removes a major downside surprise but doesn't materially raise the bar. Seeking Alpha Presentation Read More.
• Neutral Sentiment: Company provided an earnings presentation and business-update materials that investors can review for product/timing details — useful for longer-term conviction but mixed near-term impact. Earnings Presentation
• Negative Sentiment: Q1 EPS missed materially: reported $0.25 vs. consensus $0.73 — a significant earnings miss that introduces execution risk and could cap gains if the company can't demonstrate a clear path to margin recovery. Press Release / Slide Deck

Analysts Set New Price Targets

ONC has been the subject of a number of research reports. Sanford C. Bernstein upgraded BeOne Medicines from a "hold" rating to an "outperform" rating and set a $414.00 price objective for the company in a research report on Monday, January 12th. Morgan Stanley reiterated an "overweight" rating and set a $395.00 price objective on shares of BeOne Medicines in a research report on Thursday. Weiss Ratings reiterated a "sell (d-)" rating on shares of BeOne Medicines in a research report on Monday, April 20th. Wall Street Zen cut BeOne Medicines from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 28th. Finally, Guggenheim upped their price objective on BeOne Medicines from $410.00 to $420.00 and gave the company a "buy" rating in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $391.00.

Insider Buying and Selling

In other BeOne Medicines news, SVP Chan Henry Lee sold 332 shares of the company's stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $311.59, for a total value of $103,447.88. Following the completion of the sale, the senior vice president owned 318,370 shares in the company, valued at $99,200,908.30. This represents a 0.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.62% of the stock is currently owned by insiders.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.